Amkor Technology Free cash flow decreased by 137.4% to -$79.52M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 42.6%, from -$55.75M to -$79.52M. Over 3 years (FY 2022 to FY 2025), Free cash flow shows relatively stable performance with a 0.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $116.28M | $201.32M | $8.02M | $114.04M | -$151.80M | $220.20M | $77.52M | $62.75M | $44.26M | $336.02M | $66.14M | $58.38M | $0.00 | $251.88M | -$55.75M | $112.27M | -$77.93M | $212.40M | -$79.52M |
| QoQ Change | — | +73.1% | -96.0% | >999% | -233.1% | +245.1% | -64.8% | -19.1% | -29.5% | +659.1% | -80.3% | -11.7% | -100.0% | — | -122.1% | +301.4% | -169.4% | +372.5% | -137.4% |
| YoY Change | — | — | — | -1.9% | — | +9.4% | +866.1% | -45.0% | +129.2% | +52.6% | -14.7% | -7.0% | -100.0% | -25.0% | -184.3% | +92.3% | — | -15.7% | -42.6% |